Medtronic PLC (NYSE:MDT) stock price target increased to $94.55, issued a report today by Vetr Inc.
- Updated: October 16, 2016
In a report released on 10/11/2016 Vetr Inc. increased the stock price target of Medtronic PLC (NYSE:MDT) to $94.55 indicating a possible upside of 0.14%.
Previously on 8/26/2016, Needham reported about Medtronic PLC (NYSE:MDT) raised the target price from $93.00 to $95.00. At the time, this indicated a possible upside of 0.11%.
Yesterday Medtronic PLC (NYSE:MDT) traded -0.72% lower at $83.19. The company’s 50-day moving average is $86.02 and its 200-day moving average is $83.89. The last stock close price is down -1.40% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 4,042,241 shares of the stock were exchanged, down from an average trading volume of 4,132,060
See Chart Below
Medtronic PLC has a 52 week low of $71.03 and a 52 week high of $89.27 with a PE ratio of 32.18 Medtronic PLC’s market capitalization is currently $0.
In addition to Vetr Inc. reporting its stock price target, a total of 22 brokerages have issued a ratings update on the company. The average stock price target is $88.75 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Medtronic PLC (NYSE:MDT)
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.